Assessing cardiac risk using heart rate variability in a phase II study of androgen-deprivation therapy and bevacizumab in noncastrate metastatic prostate cancer patients.
Year: 2010
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: G. Gibney, A. Elfiky, C. J. Hoimes, A. Burns, E. Rowen, J. A. McDonough, R. Lampert, C. Gross, W. K. Kelly
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2590910998